Raised risk of prostate cancer in Black men

NewsGuard 100/100 Score

Black men living in England are three times more likely to get prostate cancer than White men and tend to be diagnosed five years younger, researchers have found.

The PROCESS study is the first population-based study to compare rates of prostate cancer between Black men and White men living in the United Kingdom. Researchers at Bristol University's Department of Social Medicine carried out the study in collaboration with colleagues at Bristol Royal Infirmary, Southmead Hospital, and in London.

Studies in the US had already reported a higher rate of prostate cancer in Black men, but it was unclear if this reflected a higher rate of diagnosis, or a difference in disease biology.

In the UK study, published in the British Journal of Cancer, the difference between black men and white men exceeded that in the US, and could not be fully explained by differences in how long the men delayed before seeing their doctor, differences in access to diagnostic services, or by differences in the information black men or white men had about the condition. Indeed, a higher average level of prostate specific antigen in Black men at diagnosis suggested that the difference in rates may be underestimated.

Dr Chris Metcalfe, Lecturer in Medical Statistics and collaborator on the project, said: "This is the first evidence from the UK on differences between Black and White men in rates of prostate cancer. "

He added: "There are very few known risk factors for prostate cancer but as we exclude a role for social factors, such as access to diagnostic services, it looks more likely that the higher rate in Black men is due to a biological susceptibility to developing the disease."

The researchers are now doing further work to see if there are differences in disease progression and survival following diagnosis between the two groups.

The paper, Pathways to diagnosis for Black men and White men found to have prostate cancer: the PROCESS cohort study, C Metcalfe, S Evans, F Ibrahim, B Patel, K Anson, F Chinegwundoh, C Corbishley, D Gillatt, R Kirby, G Muir, V Nargund, R Popert, R Persad and Y Ben-Shlomo on behalf of the PROCESS study group, British Journal of Cancer, advance online publication 16 September 2008.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer